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Active smoking is a major preventable public health problem and an established critical factor for epigenetic
modification. In this systematic review, we identified 17 studies addressing the association of active smoking
exposure with methylation modifications in blood DNA, including 14 recent epigenome-wide association studies
(EWASs) and 3 gene-specific methylation studies (GSMSs) on the gene regions identified by EWASs. Overall, 1460
smoking-associated CpG sites were identified in the EWASs, of which 62 sites were detected in multiple (≥3)
studies. The three most frequently reported CpG sites (genes) in whole blood samples were cg05575921 (AHRR),
cg03636183 (F2RL3), and cg19859270 (GPR15), followed by other loci within intergenic regions 2q37.1 and 6p21.33.
These significant smoking-related genes were further assessed by specific methylation assays in three GSMSs and
reflected not only current but also lifetime or long-term exposure to active smoking. In conclusion, this review
summarizes the evidences for the use of blood DNA methylation patterns as biomarkers of smoking exposure for
research and clinical practice. In particular, it provides a reservoir for constructing a smoking exposure index score
which could be used to more precisely quantify long-term smoking exposure and evaluate the risks of smoking-
induced diseases.
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Tobacco smoking is a major public health problem,
globally associated with substantial preventable morbid-
ity [1]. In particular, active smoking in adults accounts
for a large share of a wide spectrum of chronic diseases,
including various forms of cancer, respiratory, and car-
diovascular diseases. DNA methylation, one of the main
forms of epigenetic modifications, has recently been sug-
gested to play an important role in the pathways of
smoking and smoking-induced diseases [2].
Earlier epigenetic studies on active smoking generally
applied locus-specific assays to detect cytosine conversion
through PCR or DNA sequencing techniques to investigate* Correspondence: h.brenner@dkfz-heidelberg.de
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These approaches yielded several replicable smoking-
related loci in the candidate genes MAOA, MAOB, and
COMT, as well as global methylation differences [4].
Following the introduction of Infinium Human Methylation
Bead Chip (27 and 450 K) assays, numerous smoking-
related CpG sites have been discovered via epigenome-wide
association studies (EWASs), which investigated DNA
methylation in whole blood samples collected through
epidemiological studies. The first such site, cg03636183,
located in the gene F2RL3, was reported by Breitling et al.
in 2011 [5]. The so far largest EWAS by Zeilinger, reported
in 2013, discovered and validated statistically significant
differences in the methylation of 187 CpG sites between
current smokers and never smokers [6]. Based upon the
findings in EWASs, more recent studies focused on blood
DNA methylation at specific genes, such as F2RL3 and
AHRR, to further explore long-term or lifetime correlates
of active smoking exposure which might serve as bio-
markers for both current and past smoking exposure [7–9].distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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available in epidemiological studies and may be par-
ticularly relevant for systemic sequelae of smoking and
smoking-related health disorders, it is predictable that
there will be many EWASs based on whole blood sam-
ples in the near future with the spreading application of
Illumina assays. Thus, this systematic review aims to
summarize the current evidence on the association of
active smoking with whole blood DNA methylation
among adults, from EWASs and gene-specific studies
(GSMSs) on specific gene regions identified by EWASs,
to provide applicable suggestions for further smoking-
related methylation studies.
Methods
We conducted this systematic literature review according
to a predefined protocol. Reporting follows the PRISMA
statements [10].
Data sources and search strategy
A systematic literature search was conducted to identify
studies assessing smoking-related differential methyla-
tion in CpG sites in humans. Databases of PubMed and
ISI Web of Science were searched for eligible articles
until February 28, 2015. The keyword combinations used
in PubMed were as follows: (((“smoking”[MeSH Terms]
OR “smoking”[All Fields]) OR (“smoke”[MeSH Terms]
OR “smoke”[All Fields])) AND (“methylation”[MeSH
Terms] OR “methylation”[All Fields])). The search
terms used in ISI Web of Science were as follows:
TS = (((smoking*) OR (smoke)) AND (methylation)).
After filtering the duplicates by Endnote X7, and ex-
cluding ineligible articles by title and abstract review,
articles with potential relevance for the study topic
underwent full-text review.
Study selection
During title and abstract screening for potentially eli-
gible studies, we used the following exclusion criteria
(Fig. 1): 1) not published in English; 2) studies con-
ducted in non-human beings; 3) not original articles or
articles without full text; 4) no data on smoking-
methylation associations; 5) studies addressing global
methylation only; 6) studies without any significant
results; 7) studies not including adults; and 8) studies
not based on blood samples. After a full-text review,
therapy-related studies were also excluded, and the
remaining articles were finally categorized into EWASs
and GSMSs.
Data extraction and quality assessment
Two investigators (XG, MJ) independently extracted
data from the eligible studies. From each study, we sum-
marized available information on first author, country,study design, basic characteristics of samples (including
size, gender, and age distribution), type of bio-specimen,
leukocyte distribution adjustment (LDA), smoking indi-
cators, number of significant CpG sites along with their
located genes, correction for multiple testing, and esti-
mated effect sizes of smoking exposure on methylation
(expressed by β values). Effect sizes, a quantitative meas-
ure of methylation changes, were calculated between
current/former smokers and non-smokers for each CpG
site without further discrimination by exposure quantity
(effect size = median/mean βcurrent/former smoker –
median/mean βnever smoker).
We assessed the quality of each included article using
the following quality criteria: 1) clear definition and de-
scription of study population; 2) suitable ascertainment
of smoking and covariates (interviews/questionnaires or
hospital records); and 3) consideration (through stratifi-
cation or adjustment) of at least the following covariates
in the analysis: age and sex.
Microsoft Excel 2010 (Microsoft Corporation, New
Mexico, USA), SAS version 9.3 (SAS Institute Inc., Cary,
NC, USA), and Sigmaplot Ver.12.5 (Systat Software Inc.




The initial search yielded 1982 articles using the above-
described search terms, 880 from PubMed and 1102
from Web of Science (Fig. 1). Among those, we excluded
786 duplicates and 1178 by title and abstract scan. The
remaining 18 studies were selected for a full-text review,
of which one therapy-related study was excluded. Cross-
referencing revealed no further relevant records. There-
fore, 17 articles assessing the association of smoking
with blood DNA methylation were eligible for this sys-
tematic review, including 14 EWASs [5, 6, 11–22] and 3
GSMSs [7, 8, 23] which were published between 2011
and 2015 (Tables 1 and 2). Furthermore, we summarized
effect sizes of smoking exposure on all reported CpG
sites with their corresponding genes (Additional file 1:
Table S1) and plotted loci discovered by multiple (≥3)
studies with their available effect sizes (β values) in val-
idation panels (i.e., independent replication samples,
which should not be affected by the overestimation of
true associations that is to be expected in the discovery
samples [24] Fig. 2). Additionally, we used the published
data of the study by Zeilinger et al. as an example to
describe the effect size alterations of multiple discovered
loci after smoking cessation (Fig. 3) [6].
Study characteristics and results of EWASs
All EWASs applied Illumina 27 or 450 K methylation
arrays to uncover smoking-related CpG sites. Three
Pubmed Search: 880 Web of Science Search: 1102
Total: 1982
786: Duplicates
Titles and Abstracts reviewed: 1196
119: Non-English articles
191: Non-human beings studies
257: Non-original articles
433: No data on smoking methylation associations
50: No full text articles
67: Global methylation articles
21: Non-adults studies
14: No significant results
Full-text review: 18
26: Not based on whole blood samples
1: Therapy related
Included: 17
EWASs: 14 GSMSs: 3
Fig. 1 Flow diagram of systematic literature search in PubMed and Web of Science
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MALDI-TOF [5], and one used quantitative-PCR [17] as
additional supplementary measurement in their valid-
ation phases (Table 1). Six studies were from the USA,
seven from Europe (UK = 4, Germany = 2, Sweden = 1),
and one from Qatar. The population sizes varied from
107 to 1793 in discovery panels, two studies only in-
cluded males [13, 18], and four only included females
[14, 17, 19, 21]. Eight studies validated their findings fur-
ther in internal independent replication samples, while
another two studies replicated findings of significant
associations from proceeding EWASs [16, 22]. Two
studies were carried out in lymphocyte DNA [11, 17],
and twelve studies assessed methylation in whole blood
DNA. Eight studies adjusted their results for leucocyte
distribution [6, 15–18, 20–22], seven of which used the
algorithm of Houseman et al. [25]. However, five studies
emphasized that the variability in DNA methylation due
to cell composition was probably small and insignificant
when compared with the differential methylation patterns
that can be observed between smokers and non-smokers
[15–17, 20]. Family-wise error rate (FWER) or false dis-
covery rate (FDR) was applied to adjust multiple testing.
A total of 1460 CpG sites were identified in these
EWASs, 62 of them were discovered in multiple (≥3)studies. Among the latter, 47 were located in 27 genes
(35 were located in the bodies of corresponding genes),
and 15 were located in the intergenic regions (Additional
file 1: Table S1). Their effect sizes in validation samples are
summarized in Additional file 1: Table S1 (range in valid-
ation samples, −0.233 (cg05575921) to +0.157 (cg23480
021)), and compared in Fig. 2. The five sites (genes) with
the largest effect sizes were cg09935388 (GFI1), cg05575
921 (AHRR), cg23576855 (AHRR), cg06126421 (6p21.33),
and cg03636183 (F2RL3). Loci cg03636183 (F2RL3), cg055
75921 (AHRR), and cg19859270 (GPR15) were reported 12,
11, and 10 times, respectively. Other CpG sites located in
intergenic regions of 2q37.1 and 6p21.33 were reported at
least four times as well (Additional file 1: Table S1). For all
but two sites within gene MYO1G (cg12803068 and
cg22132788), smoking was associated with decreased
methylation. Eleven loci discovered in multiple (≥3) studies
were located in AHRR, followed by six loci in 2q37.1, four
loci in C14orf43, and three loci in GFI1 (Fig. 2).
Figure 3 provides a comparison of effect estimates for
these same CpG sites for current and former smokers
from the largest EWAS up to date by Zeilinger et al. [6].
A consistent pattern of effects among former smokers
that are in the same direction but much smaller than
effects among current smokers suggests the reversibility
Table 1 Characteristics summary of EWASs based on whole blood samples
First author (year) Country Discovery sample Validation sample LDAa Measurement Correction for
multiple testsb
Smoking indicatorsc Identified number
of CpGs (genes)dSize Male Mean age Size Male Mean age
(n) (%) (year) (n) (%) (year)
Guida, (2015) [21] UK 745 0 NAe NA NA NA Yesf 450 K FWER Current/former/never smoker (TQ) 461 (352)
Zaghlool, (2015)h [22] Qatar 123 35.8 37.9 – – – Yesf 450 K FDR Smoker/non-smoker 8 (4)
Besingi, (2014)h [16] Sweden 432 45.8 42.7 – – – Yesf 450 K FDR Smoker/ non-smoker 95 (66)
Dogan Mv Fau (2014)i [17] USA 111 0 48.4 62 0 49.0 Yesf 450 K/quantitative-PCR FDR Smoker/non-smoker (PY) 910 (625)
Elliott, (2014) [18] UK 192 100 48.5 NA NA NA Yesf 450 K FWER Current/former/never smoker (PY) 29 (15)
Harlid, (2014) [19] USA 908 0 55.7 200/476j 0 53.3 No 27/450 Kk FDR Current/former/never smoker
(PY, TQ)
13 (13)
Tsaprouni, (2014) [20] UK 464 70.5 55.4 356 0 60.1 Yesf 450 K FWER Current/former/never smoker 30 (15)
Shenker, (2013) [14] UK 184 0 NA 190 71.6 NA No 450 K/Pyrosequencing FDR Current/former/non -smoker (CL) 9 (4)
Sun, (2013) [15] USA 972 29.3 66.3 239 28.5 40.8 Yesf 27/450 Kk FDR Current/former/non -smoker (PY) 5 (5)
Philibert, (2013) [13] USA 107 100 22.0 NA NA NA No 450 K FDR Smoker/non-smoker (PY, CL) 3 (1)
Zeilinger, (2013) [6] Germany 1793 51.3 60.9 478 48.3 51.8 Yesg 450 K FWER Regular/occasional/former/never
smoker (ND, TQ, PY)
187 (94)
Philibert, (2012)i [11] USA 399 45.4 19.3 NA NA NA No 450 K FDR Smoker/ non-smoker (PY) 1 (1)
Wan, (2012) [12] USA 1085 54.4 57.3 369 35.8 47.5 No 27 K/Pyrosequencing FDR Current/former/never smoker (TQ, PY) 15 (14)
Breitling, (2011) [5] Germany 177 50.8 54.0 316 59.5 55.0 No 27 K/MALDI-TOFl FWER Heavy/never/former smoker 1 (1)
aLDA leukocyte distribution adjustment
bFWER family-wise error rate, FDR false discovery rate
cPY pack-year, ND numbers of cigarettes daily, TQ time of quitting smoking, CL serum cotinine levels
dPart of CpG sites located in the intergenic regions without gene annotations
eNot applicable
fThe influence of leukocyte composition was adjusted using the algorithm described by Houseman et al. [25]
gThe influence of leukocyte composition was adjusted by subtype cell count
hThis study used the data published by other studies for replicating their significant sites
iThe study was applied in the lymphocyte samples specifically
jTwo-hundred samples were analyzed by 450 K, and 476 samples were analyzed by pyrosequencing
kThe Illumina 27 and 450 K were used for exploratory and validation analysis, respectively










Table 2 Characteristics summary of GSMSs based on whole blood samples
First author (year) Country Sample Measurementa Smoking indicatorsb Gene(s) Main findinge
Size Male Age mean
(n) (%) (year)
Zhang, (2014) [8] Germany 3588 44.4 61.7 MALDI-TOF Current/former/never smoker (PY, ND, TQ) F2RL3 F2RL3 methylation strongly decreased with
current smoking intensity and with lifetime
cumulative smoking, and reached a plateau
at higher current and cumulative smoking
intensity. Methylation levels increased with
time since cessation, but the time for full
recovery was more than 20 years.
Shenker, (2013) [7] UK 81/180c 81.5/0 NRd BPP Current/former/never smoker (SD, CL) AHRR, 2q37, 6p21 Combining four gene loci of AHRR, 2q37,
and 6p21 into a single methylation index
provided high positive, predictive, and
sensitivity values for predicting former smoking
status in both test (n = 81, AUC = 0.82) and
validation (n = 180, AUC = 0.83) sample sets.
Breitling, (2012) [23] Germany 1100 66.6 58.0 MALDI-TOF Continuing smoker/quit after acute
event/quit before acute event/never smoking
F2RL3 F2RL3 were significantly associated with
smoking history of patients with CHD
(median methylation intensities at CpG_4,
continuing smoker = 0.53; quit after acute
event = 0.51; quit before acute event = 0.66;
never smoking = 0.74) (p < 0.001).
aMALDI-TOF Sequenom matrix-assisted laser desorption ionization time-of-flight mass spectrometry, BPP Bisulphite pyrosequencing
bPY pack-year, SD smoking duration, ND numbers of cigarettes daily, TQ time of quitting smoking, CL serum cotinine levels
cThe exploratory and validation analysis included 81 and 180 participants, respectively
dNot reported










Fig. 2 Effect sizes of smoking-related CpG sites reported ≥3 times (beta values of independent validation samples are shown where available).
Chr chromosome position, triangles and dots represent the mean and median of beta values, respectively
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ing was further confirmed in two studies of Tsaprouni
et al. and Guida et al. [20, 21]. They described patterns
consistent with the reversal of changes in methylation
intensity after smoking cessation and suggested the
existence of dynamic, reversible site-specific methylation
alterations due to active smoking. In addition, a study
investigating both tobacco and snuff smoking showed that
tobacco smoking, not smokeless tobacco, was involved
with DNA methylation, indicating that the majority of
methylation changes might be caused by the burnt prod-
ucts of tobacco, not its basic components [16]. Lastly, the
studies of Elliott et al. and Zaghlool et al. identified
ethnic heterogeneity of smoking-associated differential
methylation patterns in several loci [18, 22]. For in-
stance, smoking-associated differences of methylation
at cg05575921 within AHRR were significantly lower
in individuals of European origin compared to South
Asians [18]. The two studies speculated that either key
aspects of smoking behavior had not been captured or
there was a true ethnic difference in methylation re-
sponse to smoking exposure.Study characteristics and results of GSMSs
Four gene regions (F2RL3, AHRR, 2q37, and 6p21) and
their related specific CpG sites, which had been identified
by previous EWASs, were investigated in three whole
blood-based GSMSs of active smoking (Table 2) [7, 8, 23].
All three studies were from Europe (Germany = 2, UK = 1)
and population sizes varied from 261 to 3588. Two
German studies evaluated the dose-response relationship
between smoking exposure and methylation of F2RL3 by
MALDI-TOF. The earlier one also revealed strong associ-
ations of smoking with adverse outcomes of coronary
heart disease and concluded that methylation in F2RL3
might be a potential mediator of the detrimental impact of
smoking [23]. The largest gene-specific study in 2014 was
based on 3588 older adults from the general population
[8]. This study disclosed clear dose-response relationships
of F2RL3 methylation with both current and lifetime
smoking intensity, as well as with time since smoking ces-
sation. In particular, it was demonstrated that it took more
than 20 years for a full “recovery” of methylation levels.
The study by Shenker et al. assessed genome regions
AHRR, 2q37.1, and 6p21.33 via pyrosequencing [7].
Fig. 3 Effect sizes of smoking-induced methylation for current smokers and former smokers compared with non-smokers. Chr chromosome position,
used the publically available data of Zeilinger et al. (median beta values) [6]
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Active smoking is an established critical factor for epigen-
etic modifications in blood DNA [4]. To our knowledge,
this is the first systematic literature review on this topic.
We identified 17 eligible articles, which explored the associ-
ation of active smoking exposure with epigenetic changes
in blood DNA. Overall, 1460 smoking-related CpG sites
were identified in 14 EWASs, 62 of which were discovered
by multiple (≥3) studies. The most frequently reported sites
were cg05575921 (AHRR), cg03636183 (F2RL3), cg1985
9270 (GPR15), and other loci within the intergenic regions
2q37.1 and 6p21.33. Prominent findings for these
smoking-related genes were further analyzed in GSMSs to
disclose dose-response relationships of smoking intensities
and time since cessation with methylation levels. Taken
together, these studies suggest the possibility of using
methylation markers for a refined quantification of smok-
ing exposure and to better predict the risks of smoking-
related diseases.
Smoking-induced methylation could occur in many
regions of the human genome. In the annotated generegions, approximately half of the smoking-related CpG
sites are located in the body of specific genes (e.g., AHRR,
F2RL3, etc.). Notably, their effect size was commonly
higher than that of sites located at other parts, including
the 1st exon, untranslated region (UTR), and transcription
start site (TSS) (Additional file 1: Table S1, Fig. 2). Add-
itionally, about one quarter of smoking-related loci are
located in the intergenic regions, such as 2q37.1 and
6p21.3 (Additional file 1: Table S1).
For the sites located in the gene bodies, epidemiological
studies have meanwhile observed biologically plausible
associations with smoking-induced chronic diseases or
cancers. For instance, the first discovered smoking-
associated site cg03636183 is located in the body of gene
F2RL3 (the coagulation factor II receptor-like 3 gene) [5],
and was consistently confirmed in multiple EWASs and
even replicated across racial groups [15, 17–19, 22]. The
function of F2RL3 is coding the thrombin protease-
activated receptor-4 (PAR-4), which is a protein expressed
in various tissues over the body, including blood leuko-
cytes and lung tissue, and plays a key role in platelet
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why the methylation pattern of F2RL3 was found to
be related to risks for cardiovascular diseases (CVD)
and lung cancer, as well as to total mortality [26, 27].
Nevertheless, the role of F2RL3 as a potential medi-
ator or just an indicator of smoking-related risk is
still not well understood.
The strongest and most consistent associations have
meanwhile been reported for CpG sites located in the
body of AHRR, a well-known tumor suppressor. Smok-
ing could trigger the generation of polycyclic aromatic
hydrocarbons (PAHs) that affects the aryl hydrocarbon
receptor (AHR), leading to alterations in the expression
(and methylation status) of AHRR [3]. Thus, this gene
could mediate detoxification of PAHs and might be
involved in the metabolism of endogenous toxins from
cigarette smoking [28]. A recent study by Zhang et al. dis-
closed clear dose-response relationships of AHRR methyla-
tion with both current and lifetime smoking exposure, as
well as with smoking-related mortality outcomes [29].
Methylation at cg05575921in AHRR and a locus in 6p21.33
were additionally suggested to be promising candidates for
enhancing cardiovascular risk prediction [29].
Irrespective of full understanding of the pathophysio-
logical mechanisms, strong and consistent associations
with smoking of a variety of CpG sites suggest their
potential use as main correlates for smoking exposure.
Two GSMSs have demonstrated the potential of several
sites within F2RL3 as promising biomarkers for both
current and past smoking exposure [8, 23]. A recent
study has identified that cg05575921 within AHRR was
both sensitive and specific for current smoking in adults
with an area under the curve (AUC) of 0.99, and efforts
evaluating methylation of cg05575921 as a biomarker to
guide smoking cessation are ongoing [30]. Further stud-
ies on loci within more smoking-related genes are in
need to explore precise dose-response relationships to
describe smoking exposure globally and understand their
molecular mechanisms comprehensively.
In addition to the critical sites in gene bodies, there
are several smoking-related sites within other genome
regions, such as cg19859270, which are located at the
1stExon of gene GPR15 (G-protein-coupled receptor
15), and several loci in the intergenic region 2q37.1.
These sites might make additional contributions to
smoking exposure evaluation through a smoking-related
methylation signature. Along with the significant loci in
AHRR and F2RL3, they could facilitate the construction
of a quantitative approach with better specificity to dif-
ferentiate never smokers from former smokers (validated
AUC = 0.83, positive predictive value = 0.85) [7]. In 2012,
GPR15 was first reported in the study of Wan et al.,
along with its relationships with current and long-term
smoking [12]. Afterwards, the study of Tsaprouni et al.presented that this gene was the only one showing a
clear trend of increased gene expression in smokers
compared to non-smokers with a prominent negative
correlation between gene expression and methylation
[20]. The author thus presumed that the reduction of
methylation levels of locus cg19859270 within GPR15 in
smokers would lead to increased transcription. This dif-
ferential expression of GPR15 in smokers compared with
never smokers was further confirmed by recent studies
of Bauer et al. and Kõks et al. [31, 32]. In addition, as an
HIV co-receptor, this gene was recently reported to
interact with the ethnicity-dependent differential preva-
lence of HIV, especially HIV2 in African Americans [33].
Moreover, the six significant sites in locus 2q37.1 are
directly located adjacent to a cluster of alkaline phos-
phatase genes [34].
In the implementation and interpretation of EWASs
and GSMSs based on blood samples, a potential limita-
tion deserving particular attention is that whole blood
DNA represents a mixture of DNA from various types
of leucocytes that show partly different methylation pat-
terns. Hence, smoking-related differential methylation
may, in theory, partly reflect smoking-related shifts in
leucocyte distribution. The majority of EWASs adjusted
their analysis for leucocyte distribution with the algorithm
of Houseman et al. [25]. However, although smoking is
known to increase the overall numbers of leucocytes [35],
the impact on leucocyte distribution still remains unclear
[15–17, 20, 21]. Recently, GPR15 methylation has been
shown to be linked with chronic inflammation via regulat-
ing T cell migration [32], which raised the possibility that
for some loci, like GPR15, differential methylation might
reflect a shift in blood cell mixture. On the other hand, a
recent study compared the smoking-related methylation
profiles in both buccal and whole blood samples and
found that effect sizes in blood samples were similar to
that in buccal samples [36]. This suggests that cell type
distribution has no major impact for the majority of
smoking-related differential methylation. Nevertheless,
even if smoking-related methylation patterns were partly
due to confounding by leucocyte distribution, they might
still be useful as biomarkers for smoking exposure.
Our review was limited to smoking-associated DNA
methylation changes among adults. Similar to the find-
ings in adults, EWASs investigating the role of maternal
smoking in newborns also identified differentially methyl-
ated CpG sites in several smoking-related genes, such as
AHRR, MYO1G, and GFI1, but with less pronounced
effect sizes. Interestingly, several loci, such as cg23067299
(AHRR) and cg05549655 (CYP1A1), were, so far, only
discovered in studies assessing the impact of maternal
smoking in newborns, whereas none of these studies
reported differential methylation of cg03636183 (F2RL3)
and cg19859270 (GPR15), two critical loci associated with
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plained by the differences of exposure pathways and popu-
lation susceptibilities [3, 37], but more and larger EWASs
in the respective age groups are needed to further clarify
similarities and differences.
The number of known smoking-related CpG sites con-
tinues to increase. Given that smoking is an established
risk factor for many chronic diseases, these loci could have
important applications as objective biomarkers of both
current and lifetime smoking exposure and for quantifying
risks of smoking-related diseases. Recent GSMSs have
already demonstrated strong dose-response relationships
between methylation signatures and current and lifetime
smoking exposure, as well as time since cessation of
smoking [7, 8]. Furthermore, strong associations have
been demonstrated between methylation signatures and a
variety of major disease endpoints, including coronary ar-
tery diseases, lung cancer, and asthma [29, 38–41]. With
further refinement of methylation signatures and further
evaluation of the predictive value for these and additional
disease outcomes, smoking-related methylation signatures
might become a valuable tool for enhanced risk stratifica-
tion and risk-adopted screening and treatment decisions
in clinical practice. As a promising example, Teschendorff
et al. constructed a smoking index score and subsequently
showed that it was able to discriminate normal tissue from
cancer tissue rather well [36], thereby demonstrating that
smoking-related methylation indices could be useful risk
indicators of smoking-induced health disorders.
This review has specific strengths and limitations.
Strengths include the comprehensive search in two main
databases, as well as strict adherence to standards of study
selection, classification, and reporting. However, despite
this comprehensive search strategy, we cannot exclude the
possibility of having missed relevant studies, especially
studies reported in languages other than English, or with-
out full-length reports. Second, in most studies, smoking
exposure was exclusively ascertained by self-reporting
which is known to be less than perfect and most likely led
to underestimation of true effects. Finally, our review was
restricted to methylation patterns in blood DNA associated
with active smoking. The focus on this sample matrix was
a conscious decision due to its special relevance and ubi-
quitous availability in large epidemiological as well as rou-
tine point-of-care settings. Future research should address
specific smoking-associated methylation signatures in vari-
ous types of tissues (e.g., tumor samples, buccal cells). Also,
apart from active smoking, methylation signatures reflect-
ing passive smoking would be of major interest.Conclusions
In summary, since the first discovery of smoking-related
differential DNA methylation by Breitling et al. in 2011[5], methylation of a large number of CpG sites has been
consistently shown to be affected by smoking exposure.
With few exceptions, active smoking was associated with
reduced methylation levels, and smoking-related changes
in methylation turned out to be reversible, with inter-
mediate methylation levels among former smokers com-
pared to current and never smokers. However, several
studies have shown that it may take up to 20 years to
reach a full “methylation recovery” [8, 21]. Even though
whole blood DNA presents a mixture of leucocytes sub-
types, methylation of DNA from whole blood samples
seems to be a powerful and highly informative bio-
marker not only for current smoking but also for life-
time history of smoking. Preliminary data suggest that
smoking-related methylation signatures may also be very
useful predictors of smoking-associated risks. Further
research should aim for refinement of smoking-related
methylation signatures and for their comprehensive val-
idation with respect to a variety of disease outcomes in
large epidemiological studies in order to best define the
use of such signatures for research and clinical practice.
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